JERUSALEM, Israel, July 28 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. , a developer of oral delivery systems, announced today that Dr. Harold Jacob has been named to the Company's Board of Directors.
Dr. Jacob is presently CEO of NanoVibronix, an Israeli biotech company. He has served as the Director of Medical Affairs at Given Imaging Ltd. and has advised a wide spectrum of companies, including Med-Dynamix Ltd. and Ballard Medical.
"The addition of Dr. Jacob's extraordinary scientific expertise and business acumen to Oramed's Board of Directors will significantly strengthen the Company and help us achieve our goals," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "I am very excited that Dr. Jacob is joining our team and confident that his talents, experience and professionalism will enable Oramed to further establish itself as a leader in the development of oral delivery solutions."
"I am proud to join the Board of this very innovative company and hope to contribute to its historic goal of bringing the first oral insulin preparation to market," said Dr. Jacob.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
CONTACT: Company and Investor Relation Contacts: Oramed Pharmaceuticals,
Eric Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, Email:
eric@oramed.com; Media Contacts: Ruder Finn Israel for Oramed, Matthew
Krieger, Cell: +972-54-467-6950, Office: +972-2-589-2003, Email:
matthew@oramed.com
